Background: Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD) trials; the placebo response of devices such as repetitive transcranial magnetic stimulation (rTMS) has not been systematically assessed. We proposed to assess placebo responses in two categories of MDD trials: pharmacological (antidepressant drugs) and non-pharmacological (device- rTMS) trials. Methodology/Principal Findings: We performed a systematic review and meta-analysis of the literature from April 2002 to April 2008, searching MEDLINE, Cochrane, Scielo and CRISP electronic databases and reference lists from retrieved studies and conference abstracts. We used the keywords placebo and depression and escitalopram for pharma...
The placebo effect across psychiatric disorders is still not well understood. In the present study, ...
Background: Major depressive disorder is one of the most common, burdensome, and costly psychiatric...
Background Roughly 80% of the symptom improvement experienced on antidepressants in clinical trials ...
Background: Although meta-analyses have shown that placebo responses are large in Major Depressive D...
Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD...
Background: Although meta-analyses have shown that placebo responses are large in Major Depressive D...
Background: Placebo response is common in patients with major depressive disorder (MDD) and decrease...
Background: For many years, placebo has been defined by its inert content and use in clinical trials...
Background: Previous studies have shown that placebo response rates in antidepressant trials have be...
Item does not contain fulltextImprovements in placebo groups of antidepressant trials account for a ...
BACKGROUND: Major Depression (MD) and treatment-resistant depression (TRD) are worldwide leading cau...
BACKGROUND Previous studies have shown that placebo response rates in antidepressant trials have ...
Background: The increasing rate of failure of antidepressant trials in major depressive disorder (MD...
The issue of unblinded outcome-assessors and patients has repeatedly been stressed as a flaw in alle...
A meta-analysis was performed on 19 studies comparing antidepressant medication to placebos, and on ...
The placebo effect across psychiatric disorders is still not well understood. In the present study, ...
Background: Major depressive disorder is one of the most common, burdensome, and costly psychiatric...
Background Roughly 80% of the symptom improvement experienced on antidepressants in clinical trials ...
Background: Although meta-analyses have shown that placebo responses are large in Major Depressive D...
Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD...
Background: Although meta-analyses have shown that placebo responses are large in Major Depressive D...
Background: Placebo response is common in patients with major depressive disorder (MDD) and decrease...
Background: For many years, placebo has been defined by its inert content and use in clinical trials...
Background: Previous studies have shown that placebo response rates in antidepressant trials have be...
Item does not contain fulltextImprovements in placebo groups of antidepressant trials account for a ...
BACKGROUND: Major Depression (MD) and treatment-resistant depression (TRD) are worldwide leading cau...
BACKGROUND Previous studies have shown that placebo response rates in antidepressant trials have ...
Background: The increasing rate of failure of antidepressant trials in major depressive disorder (MD...
The issue of unblinded outcome-assessors and patients has repeatedly been stressed as a flaw in alle...
A meta-analysis was performed on 19 studies comparing antidepressant medication to placebos, and on ...
The placebo effect across psychiatric disorders is still not well understood. In the present study, ...
Background: Major depressive disorder is one of the most common, burdensome, and costly psychiatric...
Background Roughly 80% of the symptom improvement experienced on antidepressants in clinical trials ...